15 March 2023: Articles
Neurotuberculosis in a Patient with Ulcerative Colitis Using Long-Term Adalimumab: A Rare Case
Challenging differential diagnosis, Rare diseaseCarolina Bortolozzo Graciolli Facanali1ADE*, Marcio Roberto Facanali Junior1BCE, Adriana Vaz Safatle-Ribeiro1AE, Carlos Walter Sobrado1ADE
Am J Case Rep 2023; 24:e938353
BACKGROUND: Tuberculosis (TB), a global public health problem, is a disease with a high incidence and prevalence worldwide. The risk of developing TB increases after starting anti-tumor necrosis factor (TNF) therapy in the management of ulcerative colitis (UC). Isolated neurotuberculosis (NTB) without other manifestations is a rare form of infection in these patients. This article reports a case of a severe UC patient with isolated NTB following long-term therapy with adalimumab and discusses the clinical aspects, diagnosis, management, and prognosis.
CASE REPORT: A 34-year-old female patient with severe UC with pancolitis reported continuous and progressive holocranial headaches associated with a daily fever of 38°C and night sweats after 4 years of using adalimumab and after being in deep remission. Annually, she was screened for latent TB with chest X-rays and a Mantoux tuberculin skin test, and she always had negative results for TB. On cerebral magnetic resonance imaging with post-contrast sequences, small cortical lesions in the left frontal lobe and 2 larger lesions were visualized and were suggestive of tuberculomas. The initial management consisted of the suspension of immunosuppressive therapy and treatment with rifampicin, isoniazid, ethambutol, pyrazinamide, and prednisone. The patient showed clinical and neurological improvement and was clinically asymptomatic, with no changes in laboratory tests. Also, she had no neurological sequelae and was taking maintenance therapy with prednisone as indicated by the neurologist.
CONCLUSIONS: Early recognition of symptoms of neurological involvement of TB, suspension of anti-TNF and adequate treatment are fundamental steps to prevent complications.
Keywords: adalimumab, Colitis, Ulcerative, tuberculoma, Tuberculosis, Central Nervous System
Tuberculosis (TB) is considered a worldwide public health problem and is a disease with high incidence and prevalence worldwide. It is estimated that one-third of the world’s population has latent TB, and approximately 10 million people had TB in 2019, including 32% of women over 15 years of age .
The 2 main forms of inflammatory bowel disease (IBD) are Crohn disease and ulcerative colitis (UC); these immune-mediated conditions are characterized by chronic inflammation, with periods of remission and exacerbation. UC affects the mucosa and submucosa of the colorectal segment and, in more severe cases, causes bleeding and ulcers . There is no clinical intervention that can cure the disease. Adequate treatment for UC is still quite limited, and constant searches for new forms of treatment are currently underway. In the past 2 decades, the management of UC has evolved, especially due to the increasing use of biological agents worldwide. However, the use of biological products such as infliximab and adalimumab, which both neutralize tumor necrosis factor alpha (TNF-α) and have immunomodulatory and immunosuppressive actions, increases the risk of serious and/or opportunistic infections, such as TB . There is a high prevalence of tuberculosis in emerging countries, and the use of anti-TNF in patients with UC increases the risk of atypical reactivation of its latent form or primary infections.
In this article, we aimed to report a case of neurotuberculosis (NTB) in a female patient with UC 4 years after the start of therapy with adalimumab and to discuss the clinical aspects, diagnosis, management, and prognosis.
This case report describes a 34-year-old female patient who had severe pancolitis UC (Figure 1) since the age of 20 years. UC was diagnosed during an emergency hospitalization in which the patient presented with bloody diarrhea with mucous that occurred at a frequency of 10 episodes a day, and the diarrhea was associated with painful abdominal cramps. The patient also felt urgent evacuation that had been gradually worsening for more than 5 months; in addition, the patient had changes in her inflammatory markers, with an increased C-reactive protein level and iron deficiency anemia. A colonos-copy was performed at that time, which showed severe pancolitis, characterized by hyperemia, continuous edema from the rectum to the cecum, erosions and ulcerations throughout the colon and rectum, and friability of the mucosa. Initially, for the rescue of severe acute colitis, the patient received intravenous corticosteroids on admission, but there was no response. Then, after carrying out all the screening tests that are recommended for starting biological therapy, including a Mantoux test, which was negative, infliximab was started with a good response. The patient was discharged with maintenance infliximab in combination with azathioprine, which she took for 2 years. The patient required drug optimization due to non-healing of the mucosa but had a loss of secondary response, and the patient’s drug therapy was changed to monotherapy adalimumab, which she had been taking for the past 4 years.
In a routine consultation at an IBD outpatient clinic of a reference hospital in Brazil, she reported continuous and progressive holocranial headaches in the last 20 days, which were associated with daily afternoon fevers of 38 and night sweating. She denied any other symptoms. She denied exposure to TB or familiarity with TB.
Her laboratory tests showed no evidence of anemia, changes in leukocytes, or changes in C-reactive protein. Colonoscopy with biopsies for cytomegalovirus testing and testing for other infections were also performed, and no abnormalities were noted. The analysis of cerebrospinal fluid showed protein, 32 mg/dL; glucose, 59 mg/dL; lactate, 13.8 mg/dL; leukocytes, 1/mm3; red blood cells, 0; and adenosine deaminase, 0.01 u/L. The patient had negative Chinese ink, fungal culture, ELISA cysticercosis, toxoplasmosis immunofluorescence, cytomegalovirus, VDRL, and HTLV I and II tests.
On cerebral magnetic resonance imaging, small enhancing cortical lesions in the left frontal lobe and 2 other larger lesions in the left temporal lobe and right frontal lobe were found and were suggestive of tuberculomas, the larger measuring approximately 10 mm (Figure 2). The diagnostic hypothesis of NTB was raised, and treatment was started.
Sustained deep remission was maintained with adalimumab for 4 years. Annually, she was screened for latent TB with chest X-rays and a Mantoux tuberculin skin test, and the TB test results were always negative.
The initial management consisted of the suspension of immunosuppressive therapy and treatment with rifampicin, isoniazid, ethambutol, pyrazinamide, and prednisone. At the time of this report, 12 months after the diagnosis, the patient showed clinical and neurological improvement and was clinically asymptomatic, with no changes in her laboratory tests and without neurological sequelae. Her disease was maintained with prednisone, as indicated by the neurologist. A new colonoscopy was scheduled to define her maintenance drug treatment.
TNF-α is a pro-inflammatory cytokine that acts in the formation and maintenance of granulomas in response to intracellular organisms and has an important role in the pathogenesis of chronic inflammatory diseases and other immune-mediated diseases, whether in the activation, differentiation, and recruitment of different immune cells . With the emergence of immunobiological antibodies to TNF-α, the reality in the management of IBD, whether UC or Crohn disease, with moderate to severe disease has changed. These agents are able to delay the natural course of the disease, decrease the number of surgeries, and improve the quality of life of patients .
Anti-TNFs critically alter the regulation of inflammatory processes and apoptosis pathways and the activation, recruitment, and differentiation of cells, reducing tissue damage. There is no doubt about the benefit of using anti-TNFs in patients with UC. However, in addition to their limited effectiveness, these drugs are not entirely harmless and have relevant adverse effects, such as the development of severe infections . In this context, when neutralizing TNF-α, there is an immunomodulatory and immunosuppressive action, as TNF-α interferes with the granulomatous immune response , increasing the risk of serious and/or opportunistic infections, among which TB is one of the most frequent .
After starting anti-TNF therapy, the risk of developing TB increases by 1.6 to 25 times [6–9]. In TB-endemic countries, the risk of developing active TB in patients using anti-TNF is 10%. There is evidence that this occurs, on average, 12 weeks after starting treatment . In addition, anti-TNF therapy increases not only the risk of developing active TB  but also the reactivation of TB, leading to the development of more serious complications, dissemination to extrapulmonary sites, and worse outcomes . The high risk for the development of TB may be related to the reduction in CD8+ cells responsible for the antimicrobial activity against
The extrapulmonary involvement of TB affects approximately 15% of patients. The involvement of the central nervous system is considered one of the most serious extrapulmonary disorders of TB . NTB is the most severe form of TB  and is responsible for 1% to 5% of the cases of extrapulmonary involvement [1,14,15]. TB in the central nervous system is usually due to the spread of pulmonary infection, rarely occurs in isolation, and usually occurs with the presence of tuberculomas , as reported in this case. When it occurs, association with lung disease is more common (approximately 59% of cases). A delayed diagnosis can lead to worse outcomes, with high morbidity and mortality .
Isolated NTB without other manifestations is a rare form of infection in patients with IBD taking anti-TNF. As seen in our case report, a patient with UC developed isolated disease. The diagnosis of this condition is based on the presence of suspicious symptoms and the biochemical analysis of the cerebro-spinal fluid, and the diagnosis is confirmed by the detection of tuberculosis bacillus in the cerebrospinal fluid.
In patients taking anti-TNF medications and with the use of new technologies, the understanding of the pathogenesis of the development of latent TB to active disease and the discovery of new biomarkers are necessary . The tuberculin skin test has high sensitivity, and in a recent study, it minimized false-negative results in the identification of patients with TB when compared with the interferon-γ release assay (IGRA) .
In immunosuppressed patients, especially patients on anti-TNF or steroids and patients with HIV or TB, screening tests may not identify latent infections. That is, patients with IBD taking anti-TNF medications have an increased risk for false negativity on the tuberculin skin test and IGRA .
We understand that the diagnosis of NTB would be facilitated by the identification of
Physicians and health personnel that treat patients with IBD should continue to actively and routinely search for latent TB through periodic reevaluations with targeted consultation and should note classic TB symptoms, such as cough, fever, weight loss, night sweating, performance laboratory tests, chest X-ray, and tomography, even when patients have taken the medication for a long period, since there is no single criterion standard test for detecting the disease .
Early recognition with the correct diagnosis, suspension of anti-TNF drugs, and early treatment are fundamental steps for therapeutic success, and these could avoid disease aggravation and reduce sequelae, neurological complications, and mortality.
The reported case is important because it was a patient with isolated TB in the central nervous system without pulmonary involvement, and the patient had underlying UC and took adalimumab. Even in patients undergoing anti-TNF-α therapy for a long time, the possibility of TB should always be considered in the presence of a fever of unknown origin.
FiguresFigure 1.. First colonoscopy image at the time of ulcerative colitis diagnosis. The colonic mucosa was friable and intensely erythematous, with ulcers in a diffuse circumferential distribution. Figure 2.. Magnetic resonance T1 image section cross showing tuberculomas (red arrows) in the left temporal lobe and the other in the right frontal lobe, both measuring approximately 10 mm.
1.. Chin JH, Neurotuberculosis: A clinical review: Semin Neurol, 2019; 39(4); 456-61
2.. Danese S, Fiocchi C, Ulcerative colitis: N Engl J Med, 2011; 365(18); 1713-25
3.. Facanali M, Bortolozzo Graciolli Facanali C, Rodrigues Boarini L, P088 Neurotuberculosis in a patient with ulcerative colitis using adalimumab for a long period in Brazil: J Crohn’s Colitis, 2021; 15(Suppl. 1); S187-S89
4.. Roach DR, Bean AG, Demangel C, TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection: J Immunol, 2002; 168(9); 4620-67
5.. Colombel JF, Panaccione R, Bossuyt P, Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial: Lancet, 2017; 390(10114); 2779-89 Erratum in: Lancet. 2018;390(10114):2768
6.. Ali T, Kaitha S, Mahmood S, Clinical use of anti-TNF therapy and increased risk of infections: Drug Healthc Patient Saf, 2013; 5; 79-99
7.. Shivaji UN, Sharratt CL, Thomas T, Review article: Managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease: Aliment Pharmacol Ther, 2019; 49(6); 664-80
8.. Mañosa M, Domènech E, Cabré E, Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: Still room for improvement: J Crohns Colitis, 2013; 7(10); e499-500
9.. Winthrop KL, Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor: Nat Clin Pract Rheumatol, 2006; 2(11); 602-10
10.. Tubach F, Salmon D, Ravaud P, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry: Arthritis Rheum, 2009; 60(7); 1884-94 Erratum in: Arthritis Rheum. 2009;60(8)2540
11.. Dobler CC, Biologic agents and tuberculosis: Microbiol Spectr, 2016; 4(6); TNMI7-0026-2016
12.. Bruns H, Meinken C, Schauenberg P: J Clin Invest, 2009; 119(5); 1167-77
13.. Khatri GD, Krishnan V, Antil N, Saigal G, Magnetic resonance imaging spectrum of intracranial tubercular lesions: One disease, many faces: Pol J Radiol, 2018; 83; e524-e35
14.. Bernaerts A, Vanhoenacker FM, Parizel PM, Tuberculosis of the central nervous system: Overview of neuroradiological findings: Eur Radiol, 2003; 13(8); 1876-90
15.. Phypers M, Harris T, Power C, CNS tuberculosis: A longitudinal analysis of epidemiological and clinical features: Int J Tuberc Lung Dis, 2006; 10(1); 99-103
16.. Schaller MA, Wicke F, Foerch C, Weidauer S, Central nervous system tuberculosis: Etiology, clinical manifestations and neuroradiological features: Clin Neuroradiol, 2019; 29(1); 3-18
17.. , Manual de recomendações para o controle da tuberculose no Brasil [Internet]: Ministério da saúde no Brasil, 2011 [cited 2021 Mar 3]. p. 34–35. Available from: [in Portuguese]http://bvsms.saude.gov.br/bvs/publicacoes/manual_recomendacoes_controle_tuberculose_brasil.pdf
18.. Getahun H, Matteelli A, Chaisson RE, Raviglione M: N Engl J Med, 2015; 372(22); 2127-35
19.. Abreu C, Afonso J, Camila Dias C, Serial tuberculosis screening in inflammatory bowel disease patients receiving anti-TNFα therapy: J Crohns Colitis, 2017; 11(10); 1223-29
20.. Banerjee R, Ali RAR, Wei SC, Adsul S, Biologics for the management of inflammatory bowel disease: A review in tuberculosis-endemic countries: Gut Liver, 2020; 14(6); 685-98
21.. Riestra S, Taxonera C, Zabana Y, Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease: Gastroenterol Hepatol, 2021; 44(1); 51-66
22 February 2023 : Case reportA 30-Year-Old Woman with an 8-Week History of Anxiety, Depression, Insomnia, and Mild Cognitive Impairment ...
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
22 February 2023 : Case reportMultidrug-Resistant Kocuria rosea and Methicillin-Resistant Staphylococcus aureus Co-Infection in a Nigeria...
Am J Case Rep In Press; DOI: 10.12659/AJCR.938761
16 March 2023 : Case reportA 64-Year-Old Man Hospitalized for COVID-19 Pneumonia and Treated with Tocilizumab Who Developed Chronic Ca...
Am J Case Rep 2023; 24:e938359
01 March 2023 : Case reportAccelerated Cardiac Allograft Vasculopathy in an Orthotopic Heart Transplant Recipient with Prior COVID-19
Am J Case Rep 2023; 24:e937955
17 Mar 2023 : Case reportDermoid Cyst of the Parotid Gland: Case Report of a Rare Entity and Review of the Literature
Am J Case Rep In Press; DOI: 10.12659/AJCR.939411
17 Mar 2023 : Case reportA Case of a Refractory Bleeding Giant Vaginal Wall Cavernous Hemangioma Successfully Managed with Sclerothe...
Am J Case Rep In Press; DOI: 10.12659/AJCR.939474
16 Mar 2023 : Case reportInitial Thrombocyte Concentrate Transfusion in Woman with Chronic Immune Thrombocytopenia Purpura (ITP) Who...
Am J Case Rep In Press; DOI: 10.12659/AJCR.938752
15 Mar 2023 : Case reportThoracic Epidural as a Rescue Analgesic in a Patient with a Continuous Erector Spinae Plane Block for Rib F...
Am J Case Rep In Press; DOI: 10.12659/AJCR.938875
Most Viewed Current Articles
13 Jul 2022 : Case reportWhistling Scrotum: An Unusual Presentation of Pneumomediastinum in the Setting of an Open Scrotal Wound
Am J Case Rep 2022; 23:e936441
06 Dec 2021 : Case reportLipedema Can Be Treated Non-Surgically: A Report of 5 Cases
Am J Case Rep 2021; 22:e934406
23 Feb 2022 : Case reportPenile Necrosis Associated with Local Intravenous Injection of Cocaine
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case reportEdwardsiella tarda: A Classic Presentation of a Rare Fatal Infection, with Possible New Background Risk Fac...
Am J Case Rep 2021; 22:e934347